|
1
|
Malempati S and Hawkins DS:
Rhabdomyosarcoma: Review of the Children's Oncology Group (COG)
soft-tissue sarcoma committee experience and rationale for current
COG studies. Pediatr Blood Cancer. 59:5–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oberlin O, Rey A, Lyden E, Bisogno G,
Stevens MC, Meyer WH, Carli M and Anderson JR: Prognostic factors
in metastatic rhabdomyosarcomas: Results of a pooled analysis from
United States and European cooperative groups. J Clin Oncol.
26:2384–2389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schilbach K, Alkhaled M, Welker C, Eckert
F, Blank G, Ziegler H, Sterk M, Müller F, Sonntag K, Wieder T, et
al: Cancer-targeted IL-12 controls human rhabdomyosarcoma by
senescence induction and myogenic differentiation. Oncoimmunology.
4:e10147602015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuçi S, Rettinger E, Voss B, Weber G,
Stais M, Kreyenberg H, Willasch A, Kuçi Z, Koscielniak E, Klöss S,
et al: Efficient lysis of rhabdomyosarcoma cells by
cytokine-induced killer cells: Implications for adoptive
immunotherapy after allogeneic stem cell transplantation.
Haematologica. 95:1579–1586. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mesiano G, Leuci V, Giraudo L, Gammaitoni
L, Schianca Carnevale F, Cangemi M, Rotolo R, Capellero S,
Pignochino Y, Grignani G, et al: Adoptive immunotherapy against
sarcomas. Expert Opin Biol Ther. 15:517–528. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferrarini M, Ferrero E, Dagna L, Poggi A
and Zocchi MR: Human gammadelta T cells: A nonredundant system in
the immune-surveillance against cancer. Trends Immunol. 23:14–18.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chiplunkar S, Dhar S, Wesch D and Kabelitz
D: gammadelta T cells in cancer immunotherapy: Current status and
future prospects. Immunotherapy. 1:663–678. 2009.PubMed/NCBI
|
|
8
|
Hayday AC: [gamma][delta] cells: A right
time and a right place for a conserved third way of protection.
Annu Rev Immunol. 18:975–1026. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gober HJ, Kistowska M, Angman L, Jenö P,
Mori L and De Libero G: Human T cell receptor gammadelta cells
recognize endogenous mevalonate metabolites in tumor cells. J Exp
Med. 197:163–168. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kato Y, Tanaka Y, Miyagawa F, Yamashita S
and Minato N: Targeting of tumor cells for human gammadelta T cells
by nonpeptide antigens. J Immunol. 167:5092–5098. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gogoi D and Chiplunkar SV: Targeting gamma
delta T cells for cancer immunotherapy: Bench to bedside. Indian J
Med Res. 138:755–761. 2013.PubMed/NCBI
|
|
12
|
Liu M, Sun LL, Li YJ, Li HY, Zhang J, Li
BH and Ye ZM: Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T
cells against zoledronate-sensitized osteosarcoma cells. Int
Immunopharmacol. 28:160–167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun L, Li Y, Jiang Z, Zhang J, Li H, Li B
and Ye Z: Vγ9Vδ2 T cells and zoledronate mediate antitumor activity
in an orthotopic mouse model of human chondrosarcoma. Tumor Biol.
37:7333–7344. 2016. View Article : Google Scholar
|
|
14
|
Wrobel P, Shojaei H, Schittek B, Gieseler
F, Wollenberg B, Kalthoff H, Kabelitz D and Wesch D: Lysis of a
broad range of epithelial tumour cells by human gamma delta T
cells: Involvement of NKG2D ligands and T-cell receptor-versus
NKG2D-dependent recognition. Scand J Immunol. 66:320–328. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Clézardin P, Benzaïd I and Croucher PI:
Bisphosphonates in preclinical bone oncology. Bone. 49:66–70. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stresing V, Daubiné F, Benzaid I,
Mönkkönen H and Clézardin P: Bisphosphonates in cancer therapy.
Cancer Lett. 257:16–35. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kunzmann V, Bauer E and Wilhelm M:
Gamma/delta T-cell stimulation by pamidronate. N Engl J Med.
340:737–738. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Russell RG: Bisphosphonates: The first 40
years. Bone. 49:2–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rincon-Orozco B, Kunzmann V, Wrobel P,
Kabelitz D, Steinle A and Herrmann T: Activation of V gamma 9V
delta 2 T cells by NKG2D. J Immunol. 175:2144–2151. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mattarollo SR, Kenna T, Nieda M and Nicol
AJ: Chemotherapy and zoledronate sensitize solid tumour cells to
Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother.
56:1285–1297. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sakamoto M, Nakajima J, Murakawa T, Fukami
T, Yoshida Y, Murayama T, Takamoto S, Matsushita H and Kakimi K:
Adoptive immunotherapy for advanced non-small cell lung cancer
using zoledronate-expanded γδTcells: A phase I clinical study. J
Immunother. 34:202–211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Di Carlo E, Bocca P, Emionite L, Cilli M,
Cipollone G, Morandi F, Raffaghello L, Pistoia V and Prigione I:
Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in
combination with zoledronic acid in a preclinical model of
neuroblastoma. Mol Ther. 21:1034–1043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Braza MS, Klein B, Fiol G and Rossi JF: γδ
T-cell killing of primary follicular lymphoma cells is dramatically
potentiated by GA101, a type II glycoengineered anti-CD20
monoclonal antibody. Haematologica. 96:400–407. 2011. View Article : Google Scholar : PubMed/NCBI
|
